Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data.

clinical trials coaxial core-needle biopsy system formalin-fixed paraffin-embedded genomic analysis tissue biopsies

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 14 04 2020
accepted: 27 07 2020
entrez: 5 10 2020
pubmed: 6 10 2020
medline: 6 10 2020
Statut: epublish

Résumé

Image-guided tissue biopsies are critically important in the diagnosis and management of cancer patients. High-yield samples are also vital for biomarker and resistance mechanism discovery through molecular/genomic analyses. All consecutive patients who underwent plugged image-guided biopsy at Royal Marsden from June 2013 until September 2016 were included in the analysis. In the next step, a second cohort of patients prospectively treated within two clinical trials (PROSPECT-C and PROSPECT-R) were assessed for the DNA yield from biopsies assessed for complex genomic analysis. A total of 522 plugged core biopsies were performed in 457 patients [men, 52%; median age, 63 years (range, 17-93)]. Histological diagnosis was achieved in 501 of 522 (96%) performed biopsies. Age, gender, modality, metastatic site, and seniority of the interventionist were not found to be significant factors associated with odds of failure on a logistic regression. Seventeen (3.3%) were admitted due to biopsy-related complications; nine, three, two, one, one, and one were admitted for grade I/II pain control, sepsis, vasovagal syncope, thrombosis, hematuria, and deranged liver functions, respectively; two patients with right upper quadrant pain after liver biopsy were found to have radiologically confirmed subcapsular hematoma requiring conservative treatment. One patient (0.2%) developed grade III hemorrhage following biopsy of a gastric gastrointestinal stromal tumor (GIST). Overall molecular analysis was successful in 89% (197/222 biopsies). Prospective validation in 62 biopsies gave success rates of 92.06 and 79.03% for DNA extraction of >1 μm and tmour content of >20%, respectively. The probability of diagnostic success for complex molecular analysis is increased with plugged large coaxial needle biopsy technique, which also minimizes complications and reduces hospital stay. High-yield DNA acquisition allows genomic molecular characterization for personalized medicine.

Sections du résumé

BACKGROUND BACKGROUND
Image-guided tissue biopsies are critically important in the diagnosis and management of cancer patients. High-yield samples are also vital for biomarker and resistance mechanism discovery through molecular/genomic analyses.
PATIENTS AND METHODS METHODS
All consecutive patients who underwent plugged image-guided biopsy at Royal Marsden from June 2013 until September 2016 were included in the analysis. In the next step, a second cohort of patients prospectively treated within two clinical trials (PROSPECT-C and PROSPECT-R) were assessed for the DNA yield from biopsies assessed for complex genomic analysis.
RESULTS RESULTS
A total of 522 plugged core biopsies were performed in 457 patients [men, 52%; median age, 63 years (range, 17-93)]. Histological diagnosis was achieved in 501 of 522 (96%) performed biopsies. Age, gender, modality, metastatic site, and seniority of the interventionist were not found to be significant factors associated with odds of failure on a logistic regression. Seventeen (3.3%) were admitted due to biopsy-related complications; nine, three, two, one, one, and one were admitted for grade I/II pain control, sepsis, vasovagal syncope, thrombosis, hematuria, and deranged liver functions, respectively; two patients with right upper quadrant pain after liver biopsy were found to have radiologically confirmed subcapsular hematoma requiring conservative treatment. One patient (0.2%) developed grade III hemorrhage following biopsy of a gastric gastrointestinal stromal tumor (GIST). Overall molecular analysis was successful in 89% (197/222 biopsies). Prospective validation in 62 biopsies gave success rates of 92.06 and 79.03% for DNA extraction of >1 μm and tmour content of >20%, respectively.
CONCLUSION CONCLUSIONS
The probability of diagnostic success for complex molecular analysis is increased with plugged large coaxial needle biopsy technique, which also minimizes complications and reduces hospital stay. High-yield DNA acquisition allows genomic molecular characterization for personalized medicine.

Identifiants

pubmed: 33014822
doi: 10.3389/fonc.2020.01634
pmc: PMC7500492
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1634

Informations de copyright

Copyright © 2020 Khan, Gonzalez-Exposito, Cunningham, Koh, Woolston, Barber, Griffiths, Kouvelakis, Calamai, Bali, Khan, Bryant, Saffery, Dearman, Begum, Rao, Starling, Watkins, Chau, Braconi, Valeri, Gerlinger and Fotiadis.

Références

Nat Rev Genet. 2010 Mar;11(3):191-203
pubmed: 20125086
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
PLoS One. 2012;7(9):e45835
pubmed: 23049875
Methods. 2014 Nov;70(1):12-9
pubmed: 24561827
J Clin Oncol. 2015 Sep 1;33(25):2753-62
pubmed: 26014291
Mol Cancer Res. 2010 Sep;8(9):1175-87
pubmed: 20693306
Radiology. 2013 Jan;266(1):226-35
pubmed: 23143026
Gut. 2018 Aug;67(8):1484-1492
pubmed: 28790159
Exp Oncol. 2010 Sep;32(3):128-31
pubmed: 21403605
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
Pathol Res Pract. 1993 Feb;189(1):66-72
pubmed: 8390645
J Clin Pathol. 2014 Nov;67(11):923-31
pubmed: 25012948
Genome Biol. 2014 Aug 28;15(8):454
pubmed: 25164765
Clin Colorectal Cancer. 2017 Sep;16(3):e181-e189
pubmed: 27839727
Nat Rev Clin Oncol. 2011 Aug 02;8(10):620-5
pubmed: 21808265
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Clin Radiol. 2016 Jun;71(6):507-12
pubmed: 27040800
Lancet Oncol. 2014 Mar;15(3):267-74
pubmed: 24508104
J Vasc Interv Radiol. 2016 May;27(5):674-81
pubmed: 27017121
Cancer Discov. 2018 Oct;8(10):1270-1285
pubmed: 30166348
J Clin Pathol. 2004 Jun;57(6):654-6
pubmed: 15166276
J Clin Oncol. 2010 May 20;28(15):2635-40
pubmed: 20406927
Oncol Rev. 2013 Aug 30;7(1):e5
pubmed: 25992226
Cancer Cell. 2019 Jul 8;36(1):35-50.e9
pubmed: 31287991
Nat Rev Clin Oncol. 2011 Mar;8(3):135-41
pubmed: 21364686
Eur J Cancer. 2016 May;59:79-89
pubmed: 27017289
AJR Am J Roentgenol. 2016 Mar;206(3):655-9
pubmed: 26901024
IRB. 2012 Mar-Apr;34(2):1-8
pubmed: 22512092
J Pediatr Gastroenterol Nutr. 2016 Dec;63(6):e147-e151
pubmed: 27749391
Nature. 2011 Jul 20;475(7356):348-52
pubmed: 21776081
Radiol Clin North Am. 2015 Sep;53(5):1049-59
pubmed: 26321453
AJR Am J Roentgenol. 2010 Mar;194(3):784-9
pubmed: 20173160
Ann Oncol. 2018 Jan 1;29(1):230-236
pubmed: 29361134

Auteurs

Khurum Khan (K)

Department of Gastrointestinal Oncology, UCL Cancer Institute, University College NHS Foundation Trust, London, United Kingdom.

Reyes Gonzalez-Exposito (R)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

David Cunningham (D)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Dow-Mu Koh (DM)

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

Andrew Woolston (A)

Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.

Louise Barber (L)

Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.

Beatrice Griffiths (B)

Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.

Kyriakos Kouvelakis (K)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Vanessa Calamai (V)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Monia Bali (M)

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

Nasir Khan (N)

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

Annette Bryant (A)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Claire Saffery (C)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Charles Dearman (C)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Ruwaida Begum (R)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Sheela Rao (S)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Naureen Starling (N)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

David Watkins (D)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Ian Chau (I)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Chiara Braconi (C)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.

Nicola Valeri (N)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.
Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.

Marco Gerlinger (M)

Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.
Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.

Nicos Fotiadis (N)

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

Classifications MeSH